Tibra Equities Europe Ltd Purchases Shares of 84,445 Anavex Life Sciences Corp (AVXL)
Tibra Equities Europe Ltd purchased a new stake in Anavex Life Sciences Corp (NASDAQ:AVXL) in the 1st quarter, Holdings Channel reports. The fund purchased 84,445 shares of the biotechnology company’s stock, valued at approximately $258,000.
Other institutional investors and hedge funds have also modified their holdings of the company. Deutsche Bank AG purchased a new stake in Anavex Life Sciences during the 4th quarter worth $28,000. Geode Capital Management LLC boosted its position in Anavex Life Sciences by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 291,948 shares of the biotechnology company’s stock worth $455,000 after purchasing an additional 3,687 shares during the period. Park West Asset Management LLC boosted its position in Anavex Life Sciences by 1.6% during the 4th quarter. Park West Asset Management LLC now owns 3,495,615 shares of the biotechnology company’s stock worth $5,453,000 after purchasing an additional 53,450 shares during the period. Finally, Hikari Power Ltd purchased a new stake in Anavex Life Sciences during the 4th quarter worth $231,000. Institutional investors own 14.12% of the company’s stock.
Shares of Anavex Life Sciences stock opened at $2.75 on Wednesday. The firm has a market cap of $131.99 million, a P/E ratio of -7.05 and a beta of 2.54. Anavex Life Sciences Corp has a twelve month low of $1.25 and a twelve month high of $4.35.
A number of analysts recently weighed in on the stock. Maxim Group set a $7.00 price target on shares of Anavex Life Sciences and gave the stock a “buy” rating in a research report on Thursday, December 13th. Zacks Investment Research cut shares of Anavex Life Sciences from a “hold” rating to a “sell” rating in a research report on Monday, April 1st. Finally, Roth Capital set a $10.00 price target on shares of Anavex Life Sciences and gave the stock a “buy” rating in a research report on Friday, February 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $7.40.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.
Recommended Story: QQQ ETF
Want to see what other hedge funds are holding AVXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anavex Life Sciences Corp (NASDAQ:AVXL).
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.